<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyGuido Marcucci, Clara D. Bloomfield, Kati Maharry et al.|Journal of Clinical Oncology|2010Cited by 764
Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B StudyHeiko Becker, Clara D. Bloomfield, Michael A. Caligiuri et al.|Journal of Clinical Oncology|2009Cited by 342
<i>TET2</i> Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyKlaus H. Metzeler, Clara D. Bloomfield, Kati Maharry et al.|Journal of Clinical Oncology|2011Cited by 321
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryKlaus H. Metzeler, Clara D. Bloomfield, Heiko Becker et al.|Blood|2011Cited by 278
<i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression SignaturesJason H. Mendler, Clara D. Bloomfield, Kati Maharry et al.|Journal of Clinical Oncology|2012Cited by 268